Advertise on podcast: Maximillia Wiegand's Podcast

Description

Patients that are affected by the disease would no doubt take it despite the high price point and a lack of definitive proof of being effective. The galling part was would this be a precedent for other drug makers to use this route to fast track their approval that was otherwise reserved for a special class of drugs? Hopefully the benefit of the drug really would outweigh the cost.